Sjogren's syndrome

• Ultimate dePletion of autoReactive b cells using Obinutuzumab from sjÖgren's syndrome affected Tissues study- UPROOT study Pending
  2024-519884-16-00 4 "Sjögren's syndrome"
• An Open-Label, Phase 1b, Multiple Ascending Dose Study of OM336 in Participants with Active Sjogren’s Disease or Idiopathic Inflammatory Myo … Pending
  2025-524100-29-00 3 "Seropositive autoimmune disease: Sjogren’s disease or idiopa"
• A study to understand the safety and benefit of AlloNK® with rituximab in patients with hard-to-treat rheumatic diseases Recruiting
  2025-520461-41-00 4 2025-10-22 "Systemic Sclerosis (SSc)"
• A Phase 1b, Open-Label Study of CLN-978 for the Treatment of Active, Moderate to Severe Sjogren’s Disease Recruiting
  2025-521462-96-00 3 2025-08-05 "Sjogren's Disease"
• A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 3 Protocol to Assess the Efficacy and Safety of Nipocalimab in Adults with … Recruiting
  2024-513965-38-01 5 2025-06-16 "Sjögren's Disease"
• A randomized, two-period crossover study to demonstrate the comparability of pharmacokinetics of subcutaneous ianalumab between 2mL auto-inj … Recruiting
  2023-508996-35-00 4 2024-11-18 "Rheumatoid Arthritis"
• A study to find how well Dazodalibep works and how safe it is in participants with Sjôgren`s Syndrome Recruiting
  2023-503904-10-00 5 2024-06-07 "Sjögren’s Syndrome With Moderate-to-severe Systemic Disease "
• A study to find how well Dazodalibep works and how safe it is in participants with Sjôgren`s Syndrome Recruiting
  2024-517513-32-00 5 2025-05-16 "Sjögren’s Syndrome"
• Study to Evaluate the Efficacy and Safety of Deucravacitinib in Adults with Active Sjögren’s Syndrome Recruiting
  2023-503327-26-00 5 2024-01-31
• A study to find how well Dazodalibep works and how safe it is in participants with Sjögren’s Syndrome Recruitment ended
  2023-503923-24-00 5 2024-07-22 "Sjögren’s Syndrome With Moderate-toSevere Symptom State"
• A randomized, double-blind 2-arm NEPTUNUS extension study to assess the long-term safety and efficacy of ianalumab in patients with Sjögren’ … Recruitment ended
  2022-502966-26-01 5 2023-10-27 "Sjögren’s syndrome"
• Three-arm study of the clinical efficacy, safety and tolerability of ianalumab (VAY736) in patients with active Sjögren’s syndrome Recruitment ended
  2024-511068-10-00 5 2022-08-04 "Sjögren’s Syndrome"
• New Clinical End-points in patients with primary Sjögren’s Syndrome: an Interventional Trial based on stratifYing patients Recruitment ended
  2023-510054-16-00 4 2022-04-26 "Primary Sjogren's syndrome"
• Two-arm study of the clinical efficacy, safety and tolerability of ianalumab (VAY736) in patients with active Sjögren’s syndrome Ended
  2024-511069-12-00 5 2022-07-28 "Sjögren’s Syndrome"
• Biopsy Based Study to Understand Mechanism of Action of Ianalumab in Salivary Glands and Explore Relationships with Clinical Assessments Ended
  2023-508957-24-00 4 2022-07-27 "Sjögren's syndrome"
• RepurpSS-II study Ended
  2024-510904-36-00 4 2021-10-12 "primary Sjögren's Syndrome"

Showing 1–16 of 16 trials